Sanctuary Advisors LLC Grows Stock Position in Bristol Myers Squibb Company $BMY

Sanctuary Advisors LLC increased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 5.7% in the first quarter, Holdings Channel reports. The institutional investor owned 358,571 shares of the biopharmaceutical company’s stock after acquiring an additional 19,316 shares during the period. Sanctuary Advisors LLC’s holdings in Bristol Myers Squibb were worth $21,747,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter worth about $25,000. Swiss RE Ltd. bought a new position in Bristol Myers Squibb during the 4th quarter valued at about $25,000. Physician Wealth Advisors Inc. raised its position in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the period. Bayban bought a new stake in Bristol Myers Squibb in the fourth quarter worth about $31,000. Finally, EQ Wealth Advisors LLC bought a new stake in Bristol Myers Squibb in the fourth quarter worth about $32,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $54.00 target price on shares of Bristol Myers Squibb in a research note on Monday, July 6th. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Bank of America dropped their price objective on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 2nd. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $61.25.

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $58.73 on Thursday. The company has a market capitalization of $119.94 billion, a P/E ratio of 16.50, a P/E/G ratio of 0.16 and a beta of 0.23. The company’s 50-day simple moving average is $56.84 and its two-hundred day simple moving average is $57.72. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.16. The firm had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts anticipate that Bristol Myers Squibb Company will post 6.33 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. Bristol Myers Squibb’s payout ratio is 70.79%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Investors are focusing on Bristol Myers Squibb’s strong earnings surprise history, with recent coverage suggesting the company has the right setup to beat estimates again in its next quarterly report. Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Analysts highlighted progress in BMY’s CELMoD program, including the FDA filing for mezigdomide in relapsed or refractory multiple myeloma, which could strengthen the company’s oncology portfolio and long-term pipeline value. Can BMY’s CELMoD Program Advancements Strengthen Its Oncology Portfolio?
• Positive Sentiment: Agilent’s FDA approval for a companion diagnostic tied to Bristol Myers Squibb’s Opdivo franchise supports continued relevance for one of BMY’s key cancer drugs. Agilent Receives FDA Approval…
• Neutral Sentiment: BMY has been attracting increased user and market attention, but the coverage does not point to a specific catalyst beyond general interest in the stock. Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Wells Fargo initiated/maintained a Hold rating, signaling a cautious but not bearish view that may limit upside enthusiasm. Bristol-Myers Squibb (BMY) Gets a Hold from Wells Fargo
• Negative Sentiment: MarketWatch noted that Bristol Myers Squibb underperformed peers in Tuesday trading, suggesting some relative weakness versus other healthcare stocks. Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors
• Negative Sentiment: Septa Pharmaceuticals acquired CeeNU (lomustine) from Bristol Myers Squibb Canada, reflecting a divestiture of a legacy oncology asset rather than a growth driver. Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.